A study compared the association of semaglutide vs other antidiabetic medications and other GLP-1RAs, including liraglutide and dulaglutide, with opioid overdose risk in patients with comorbid ...

Semaglutide injections reversed some cases of MASH liver disease in clinical trials, reducing inflammation in 62.9% of patients and offering new hope for those with the life-threatening condition.

In surprising results, medical researchers have found that people who take Novo Nordisk's semaglutide-based injectables Ozempic and Wegovy seem to be strikingly less likely to die from overdosing ...

While the semaglutide shortage has been resolved, other GLP-1 medications remain in limited supply. Dulaglutide injections are still in shortage, though manufacturers report all presentations ...

Source Reference: Wang W, et al "Semaglutide and opioid overdose risk in patients with type 2 diabetes and opioid use disorder" JAMA Netw Open 2024; DOI: 10.1001/jamanetworkopen.2024.35247.

HealthDay News — For patients aged 45 years or older with type 2 diabetes, semaglutide seems to confer some advantage over empagliflozin in terms of mortality and cardiovascular event risks ...

Patients aged 45 years or older with type 2 diabetes treated from Jan. 1, 2019, to Dec. 31, 2024, with semaglutide, dulaglutide, or empagliflozin were included in the study.

Semaglutide vs. empagliflozin Overall, 7,899 patients treated with semaglutide and 7,899 treated with empagliflozin were propensity-matched (mean age, 62 years).

Risk for new semaglutide users There were 166,932 adults included in the analysis, of whom 43,620 were new users of semaglutide.